IKT Key Statistics, Chart & Performance
The current stock price of IKT is 1.5 USD. In the past month the price increased by 0.67%. In the past year, price decreased by -54.27%.
IKT Latest News, Press Relases and Analysis
IKT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About IKT
Company Profile
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Company Info
INHIBIKASE THERAPEUTICS INC
1000 N. West Street, Suite 1200
Wilmington DELAWARE 30339 US
CEO: Milton H. Werner
Employees: 16
Phone: 13022953800
INHIBIKASE THERAPEUTICS INC / IKT FAQ
What does INHIBIKASE THERAPEUTICS INC do?
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
What is the current price of IKT stock?
The current stock price of IKT is 1.5 USD. The price decreased by -0.66% in the last trading session.
Does IKT stock pay dividends?
IKT does not pay a dividend.
What is the ChartMill technical and fundamental rating of IKT stock?
IKT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for INHIBIKASE THERAPEUTICS INC?
INHIBIKASE THERAPEUTICS INC (IKT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for IKT stock?
INHIBIKASE THERAPEUTICS INC (IKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.91).
Can you provide the ownership details for IKT stock?
You can find the ownership structure of INHIBIKASE THERAPEUTICS INC (IKT) on the Ownership tab.
IKT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IKT. When comparing the yearly performance of all stocks, IKT is a bad performer in the overall market: 90.53% of all stocks are doing better.
IKT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IKT. While IKT has a great health rating, there are worries on its profitability.
IKT Financial Highlights
Over the last trailing twelve months IKT reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS increased by 66.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.87% | ||
| ROE | -65.37% | ||
| Debt/Equity | 0 |
IKT Forecast & Estimates
7 analysts have analysed IKT and the average price target is 7.14 USD. This implies a price increase of 376% is expected in the next year compared to the current price of 1.5.